Concizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), CONITEC (Brazil) and DMC (Denmark), among others, recommended or restricted concizumab, while HAS (France) did not recommend it.
The record spans 3.6 years, opening at AWMSG (Wales) on 24 Mar 2023 and running to 2 Oct 2026.
No assessment is on file from PBAC (Australia), SMC (Scotland) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for concizumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 16 of 16 records date from 2023 or later.
3 distinct indication wordings are recorded for concizumab by the agencies that label one in English (AWMSG and NICE).
AWMSG (Wales) was first to assess concizumab, on 24 Mar 2023; CONITEC (Brazil) did not open a file until 28 Jul 2026 — a wide spread of 3.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 16 dated records fall in 2026 alone.
4 of the 9 agencies here assessed concizumab more than once, G-BA (Germany) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for concizumab.
The full ledger for concizumab reads 6 recommended, 4 no benefit, 2 restricted and 2 deferred to NICE, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 28 Jul 2026 | Tratamento profilático de longa duração contra sangramentos em pacientes com hemofilia b moderadaa grave com inibidores … | incorporated into SUS | source |
| AIFA (Italy) | 1 Apr 2026 | Profilassi di routine degli episodi emorragici in pazienti con emofilia B (deficit congenito del fattore IX) con inibito… | innovative status not granted · reimbursed class A | source |
| G-BA (Germany) | 19 Mar 2026 | Alhemo — benefit assessment §35a | added benefit: not proven | source |
| CIPM (Spain) | 25 Feb 2026 | Indicaciones terapéuticas autorizadas: Alhemo está indicado para la profilaxis rutinaria de hemorragias en pacientes de … | financed by the SNS | source |
| NICE (England) | 27 Jan 2026 | NICE TA1124 | terminated appraisal | source |
11 further decisions for concizumab, across 5 agencies, are not shown here. They include the most recent record on file, 2 Oct 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- emicizumab — same ATC class B02B — Antihemorrhagics
- eltrombopag — same ATC class B02B — Antihemorrhagics
- romiplostim — same ATC class B02B — Antihemorrhagics
- avatrombopag — same ATC class B02B — Antihemorrhagics
- marstacimab — same ATC class B02B — Antihemorrhagics
- etranacogene dezaparvovec — same ATC class B02B — Antihemorrhagics
Coverage: 16 decisions for concizumab from 9 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class B02B — Antihemorrhagics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.